ArticleQuantitative imaging in medicine and surgery2025
Preoperative assessment of Ki-67 expression in hepatocellular carcinoma using a multi-parametric spectral CT approach.
Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Practical applications of photon-counting CT in oncology: an organ-based pictorial review.Insights into imaging · 2026Article
- Predictive Efficacy of a Combined Triphasic CT Radiomics and Clinical Feature Model for Ki-67 Expression in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ki-67 is a pivotal biomarker for evaluating the prognosis of hepatocellular carcinoma (HCC). This study aimed to investigate the utility of qualitative and quantitative parameters derived from spectral computed tomography (CT) in assessing Ki-67 expression in HCC. Methods: This prospective, single-center study included 89 patients (94 lesions) with pathologically confirmed HCC from February 2023 to February 2024. Participants underwent enhanced abdominal spectral CT scans within one week prior to surgery. The patients were divided into the following two groups based on the positive rate of Ki-67 (Ki-67%): a high-expression group (Ki-67 >20%, n=42); and a low-expression group (Ki-67 ≤20%, n=52). The spectral parameters assessed included CT values at 40 and 70 keV, iodine concentration (IC), the slope of the spectral Hounsfield unit (HU) curve (λHU), normalized iodine concentration (NIC) during the arterial phase (AP) and portal venous phase (PVP), and extracellular volume (ECV) fraction. Statistical significance of spectral CT parameters related to Ki-67 expression status was compared across different groups, and correlations between spectral CT parameters and Ki-67 expression levels were analyzed. Results: Significant differences were observed between the low and high Ki-67 expression groups concerning age, alpha-fetoprotein (AFP) levels, and capsule integrity (P=0.002, P=0.013, and P=0.005, respectively). Notable differences were also found in intratumoral NIC-AP, NIC-PVP, AP slope, PVP slope, and ECV fraction (P=0.017, P=0.005, P=0.001, P<0.001, and P=0.001, respectively). Meanwhile, in the comparative analysis between the low and high expression group of Ki-67, there were no statistically significant differences in the peritumoral <1 cm NIC-AP and NIC-PVP, as well as transtumoral NIC-AP and NIC-PVP levels (P>0.05). Ki-67 expression in HCC exhibited negative correlations with intratumoral NIC-AP (r=-0.248; P=0.016), NIC-PVP (r=-0.291; P=0.004), AP slope (r=-0.330; P=0.001), PVP slope (r=-0.367; P<0.001), and ECV fraction (r=-0.339; P=0.001). Conclusions: Qualitative and quantitative parameters from spectral CT provide valuable information for distinguishing between low and high Ki-67 expression in HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.